BlackRock ETF Trust is set to reorganize its BlackRock Advantage Large Cap Growth Fund into an exchange-traded fund (ETF), a move that underscores the growing popularity of ETFs in the investment landscape. This reorganization is significant as it reflects a broader trend in the financial industry, where many firms are transitioning mutual funds into ETFs to offer investors lower expenses and increased trading flexibility.
The reorganization is subject to shareholder approval and is anticipated to close at the end of trading on May 21, 2027. BlackRock believes this change will benefit investors by providing them with lower net expenses and enhanced transparency regarding portfolio holdings.
Background
BlackRock ETF Trust, incorporated in Delaware, operates as an investment entity. The firm is known for its extensive range of investment products, including ETFs and mutual funds. According to its recent filings, BlackRock has been active in reorganizing its mutual funds into ETFs, with this being the eighth such conversion in its lineup.
What the Filing Says
The SEC filing dated November 2, 2026, outlines the planned reorganization of the BlackRock Advantage Large Cap Growth Fund into the iShares Enhanced Large Cap Growth Active ETF. The filing states, "Subject to shareholder approval, the Fund is expected to be reorganized into an exchange-traded fund through the reorganization of the Fund into a newly created ETF." The filing also emphasizes that the reorganization will lead to the liquidation of the existing mutual fund.
Impact
This reorganization may affect shareholders of the BlackRock Advantage Large Cap Growth Fund, who will receive ETF shares equal in value to their current holdings, along with a cash payment for any fractional shares. The move is expected to position BlackRock more competitively in the ETF market, where low-cost options are increasingly favored by investors.
What's Next
The reorganization requires a shareholder vote due to differences in the funds' fundamental policies, particularly concerning diversification and concentration. Shareholders will receive a prospectus/proxy statement detailing the reorganization, which is expected to be disseminated around November 5, 2026.
Read Next
HCA Healthcare Executive Reports Multiple Stock Transactions
LENZ Therapeutics updates beneficial ownership in SEC filing
LOR Inc. Acquires Over 1.4 Million Shares of Rollins Inc.
Brian Magnusson Reports New Stock Transactions at Lindsay Corp
Klein Lawrence Otto Acquires 25,000 Shares in Oruka Therapeutics
Saba Capital Management boosts stake in Ellsworth Growth Fund








